The use of big data is now widespread in the U.S. health care system. At major industry conferences and in leading publications, big data has become a watchword for clinical care providers, private insurers, pharmaceutical companies, and numerous other stakeholders. In this Bulletin, leaders of Analysis Group’s Health Care practice discuss aspects of their ongoing work with big data and accompanying analytics, highlighting opportunities to improve decision making and health outcomes research initiatives.
Appreciating the implications of this new era of big data in health care requires an understanding of distinct characteristics of the data itself, including the increased quantity of data, the proliferation of new types of data, and the potential of data sets to be assessed in an overlay of one type of information over another. Our Health Care consultants discuss the opportunities to draw new insights from big data with technical and analytical expertise.
Managing Principal Mei Sheng Duh’s ongoing research in collaboration with several Analysis Group colleagues shows that patients are much more likely to report adverse “quality of life” events online than they are to signal serious clinical events.
As China’s population ages, serious and chronic diseases have become increasingly commonplace. Since 2012, Analysis Group has played an active role in broadening access to Chinese medical data to produce high-quality health care research.
Vice President Mark Gustafson and Kevin Brennan, Manager, Consulting Data, discuss the opportunities and challenges associated with the analysis of big data in health care, along with insights on the capabilities required for this type of analysis.
Managing Principals Brian Gorin and Edward Tuttle and Vice President Matthew Barrett consider opportunities and challenges associated with the clinical application of next-generation sequencing techniques.
More than five million Americans are estimated to have Alzheimer’s disease. Analysis Group research suggests that consulting with a specialist at the early stages of cognitive decline may result in reduced spending for medical services.
The increased availability of large and complex health industry data provides a basis for detailed analysis of many different types of allegedly fraudulent conduct by health care companies. Today, many pharmaceutical, biotechnology, and medical device companies, as well as other health care entities, maintain rich data sets concerning the types of marketing activities and provider relationships that are often at the heart of improper promotion and kickback allegations. Vice President Richard Mortimer considers big data analysis with respect to these allegations.
Health care institutions that are early adopters of integrated data systems now have access to rapidly growing databases containing multiple petabytes of data. Although considerations of big data in health care typically focus on patient information, health care providers also create massive quantities of internal personnel data.Vice President Dov Rothman highlights analytic opportunities created by large quantities of internal hospital personnel data that includes extensive information on numerous individuals.
A group of prominent antitrust economists that included Analysis Group Chairman Bruce Stangle, Managing Principals Paul Greenberg and Pierre Cremieux, and Principal George Kosicki, and academic affiliates Henry Grabowski, James Hughes, and Michael Wohlgenant filed an amicus curiae brief regarding the antitrust treatment of pharmaceutical patent infringement settlements.
Members of Analysis Group’s Health Care practice were recognized at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting in Montreal, Quebec. Analysis Group consultants and colleagues delivered one podium presentation and exhibited 27 posters focused on cost-of-illness and comparative effectiveness studies targeting hepatitis C, acute coronary syndrome, multiple sclerosis, sickle cell disease, HIV, hemophilia, schizophrenia, opioid abuse, and lung cancer, as well as health care resource utilization in the United States, Canada, and China.
Health Care Bulletin: Fall 2014